Increasing kidney grafts for transplantation

Musquera, Mireía; Sierra, Alba; Diekmann, Fritz; Pérez, Manuel; Mercader, Claudia; Peri, Lluís; Esforzado, Núria; Paredes, David; Alcaraz, Antonio

doi:10.1007/s00345-020-03463-x

Cited by 3 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 9 years of follow up they report only one recurrence at a site distant from the kidney graft. 1 A review article by Flechner et al discusses the ethical considerations of kidney donation with IRMs. 3 Kidneys from donors with small RCC excised with partial nephrectomy are being transplanted with good renal function and oncologic outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…The most common solid lesion in the kidney is renal cell carcinoma (RCC) and accounts for 90% of renal malignancies. 1 Surgery is curative in patients with resectable localized RCC. Given the need of expansion of the donor pool, a resected disease free kidney can be a potential organ for donation with proper surveillance.…”

mentioning

confidence: 99%

“…The excess risk of death for patients on dialysis increases 45% per additional year on the waiting list compared to patients who receive a transplant. 1 Kidney transplant represents a benefit in life expectancy of 3-15 years compared to remaining on dialysis. 1 The gap between patients in need of a kidney transplant and the organ donor pool continues to increase.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Partial Nephrectomy of Renal Cell Carcinoma From the Donor Allograft Prior to Living Donor Renal Transplantation

Cottrell-Cumber

Panchal

Wynn

et al. 2022

The American Surgeon™

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Partial Nephrectomy of Renal Cell Carcinoma From the Donor Allograft Prior to Living Donor Renal Transplantation

Cottrell-Cumber

Panchal

Wynn

et al. 2022

The American Surgeon™

View full text Add to dashboard Cite

“…The most common cancer among transplant recipients was non-Hodgkin's lymphoma (14% of all cancers in transplant recipients), lung cancer (13%), liver cancer (9%), and kidney cancer (7%) (Engels et al, 2011;Sargen et al, 2022). Compared with the general population, the risk of malignant tumors after kidney transplantation was higher, and there was a high incidence of certain types of tumors (Villeneuve et al, 2007;Au et al, 2018;Musquera et al, 2021;Rodriguez-Aguilar et al, 2021). The incidence of malignant tumors varied from region to region.…”

Section: Cancer Risk and Organ Transplantationmentioning

confidence: 99%

Cancer Risk and Mutational Patterns Following Organ Transplantation

Shen

Lian

Shi

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The rapid development of medical technology and widespread application of immunosuppressive drugs have improved the success rate of organ transplantation significantly. However, the use of immunosuppressive agents increases the frequency of malignancy greatly. With the prospect of “precision medicine” for tumors and development of next-generation sequencing technology, more attention has been paid to the application of high-throughput sequencing technology in clinical oncology research, which is mainly applied to the early diagnosis of tumors and analysis of tumor-related genes. All generations of cancers carry somatic mutations, meanwhile, significant differences were observed in mutational signatures across tumors. Systematic sequencing of cancer genomes from patients after organ transplantation can reveal DNA damage and repair processes in exposed cancer cells and their precursors. In this review, we summarize the application of high-throughput sequencing and organoids in the field of organ transplantation, the mutational patterns of cancer genomes, and propose a new research strategy for understanding the mechanism of cancer following organ transplantation.

show abstract

“…The most recent Spanish experience 6 showed that these kidney grafts are acceptable for elderly patients (> 60 years) or patients with significant comorbidities. In this study, 13 kidney allografts with SRM (mean tumor size < 2 cm) were transplanted.…”

mentioning

confidence: 99%